# MEAN DURATION OF LABOR AFTER DROTAVERINE HYDROCHLORIDE INJECTION IN THE PRIMIGRAVID WOMEN PRESENTING IN THE ACTIVE PHASE OF LABOR

### Zulfiqar Ali Khan<sup>1</sup>, Shumaila Khawaja Khail<sup>2</sup>, Mohammad Usman<sup>3</sup>

1. Assistant Professor Obs & Gyne and HOD, Swat Medical College, Saidu Sharif Swat

- 2. Assistant professor of Obs & Gyne Swat Medical College, Saidu Sharif Swat
- 3. Assistant Professor Surgery Swat Medical College, Saidu Sharif Swat

#### **ARTICLE INFO**

## **ORIGINAL ARTICLE**

Key words: Active labour, Duration, Primigravida, Drotaverine hydrochloride

#### **Corresponding author:**

Dr. Zulfiqar Ali Khan, Assistant Prof-essor Obs & Gyne and HOD, Swat Medical College Saidu Shareef Swat, +92 310 9427174,

Email: doczulf@yahoo.com

Vol 02 Issue 02 APRIL-JUNE 2024

ISSN Online: 2960-2599 ISSN Print: 2960-2580

Copyright 2023:

Pioneer Journal of Biostatistics and Medical Research (PJBMR) publishes under the policy of Creative Commons license. **Background:** The process of hastening labor involves stimulating the uterus to enhance the frequency, duration, and intensity of contractions once active phase of labor has begun. Drotaverine is an effective drug for treating spasms of the smooth muscles. However, its efficacy in shortening the duration of labor in primigravidas is not wellestablished in the local settings. Objective: Determining the mean duration of labor after Drotaverine hydrochloride injection in primigravid women presenting in the active phase of labor at a tertiary care hospital. Methodology: This caseseries study was undertaken from Feb 2023 till Dec 2023, at department of Obs and Gyne Swat Medical College Saidu Shareef Swat. The study included 150 patients who were already in the active phase of labor with cervical dilation of 3 to 5 cm with 2 to 3 uterine contractions lasting for at least 30 seconds every 10 minutes. All patients received a 40 mg injection of Drotaverine hydrochloride intramuscularly at 3 to 5 cm dilation. Then, patients were monitored until delivery, and the duration of labor from the time of injection until delivery was noted. **Results:** The mean age of the patients was 23.67 + 3.23 years. The mean length of first, second, and third stage of labor was 4.34±0.094 hours, 22.07±4.25 minutes, and 10.42±3.35 minutes, respectively. The total duration of labor was 4.94±0.33 hours.

**Conclusion:** Drotaverine hydrochloride effectively reduced the average length of labor in the primigravidas presented in the active phase of labor. Therefore, it can be administered to alleviate spasms and accelerate cervical dilatation, thereby facilitating safe and prompt delivery, and reducing the incidence of feto-maternal complications.

#### INTRODUCTION

Labor is a natural physiological process of childbirth which consists of uterine contractions, cerv-ical ripening and dilation, and the expulsion of the fetus through the vagina<sup>1</sup>. Globally, healthcare providers practice active manag-ement of labor, especially in primigravid women who face a higher risk of prolonged labor, with the aim of minimizing duration of labor and its related maternal and fetal adverse outcomes such as fetal distress, perinatal asphyxia, shoulder dystocia, prolonged hospital stay, postpartum hemorrhage, and infection <sup>2</sup>-<sup>4</sup>. In primigravid women, the first stage of labor usually lasts approximately 12-16 hours <sup>5</sup>. Cervical spasm, leading to the cervical dystocia, is a major cause of prolonged

labor<sup>6</sup>. To mitigate prolonged labor, use of antispasmodic agents is advisable to expedite the first stage of the labor, along with amniotomy and prompt administration of oxytocin <sup>7</sup>-<sup>10</sup>. Spasmolytic agents such as Drotaverine hydrochloride, Hyoscine butylbromide, Dicycl-omine, and Valethamate bromide assist in relie-ving cervical spasm and promoting cervical dilata-tion <sup>2</sup>, <sup>11</sup>-<sup>13</sup>. Drotaverine hydrochloride is a newer musculotropic spasmolytic drug and a type IV phosphodiesterase inhibitor, that is claimed to shorten labor duration by reducing cervical spasm <sup>14</sup>. In a study by Gupta et al., the mean duration of labor after Drotaverine hydrochloride injection was found to be 4.48 ± 2.26 h, with no fetal and maternal complications <sup>11</sup>. However, a Cochrane review identified low-quality evidence indicating that spasmolytic agents shorten the 1<sup>st</sup> stage of labor and increase the rate of cervical dilatation. It also found low-quality evidence showing that these drugs might reduce the total duration of labor, but there was inadequate evidence regarding the safety of these drugs <sup>7</sup>. Additionally, data is lacking regarding the impact of Drotaverine hydrochloride in reducing the duration of labor in Pakistan. So, this study intended to analyze the mean duration of labor after administering Drotaverine hydrochloride to primigravid women presenting in the active phase of labor at a tertiary care hospital.

#### **MATERIAL AND METHODS:**

Study design: Descriptive case-series study. Settings: This study was undertaken at department of Obs and Gyne Swat Medical College Saidu Shareef Swat Duration: It was accomplished in 10 months (from Feb 2023 till Dec 2023,) Sample size: A sample size of 150 was estimated with a 95% confidence level, a 1% margin of error, and a mean duration of labor of 4.48 + 2.26 hours following Drotaverine hydrochloride injection in primigravida women presenting in the active phase of labor <sup>11</sup>. Sampling technique: Purposive technique was used for sampling. Sample selection criteria: Inclusion criteria: Patients aged 18-36 years with a gestational age of  $\geq$  36 weeks, having a single fet-us with cephalic presentation confirmed by ultra-sound, and already in the active phase of Table 1: Baseline features of patients(n=150) uterine contractions lasting for at least 30 seconds every 10 minutes. Exclusion criteria: Patients with a borderline pelvis, cephalopelvic disproportion, and pregnancy complications such as gestational hypertension and gestational diabetes mellitus. Data collection procedure: After obtaining authorization from the official committee and permission from the patients, 150 patients were included in the study. Sociodemographic information was noted on a predesigned questionnaire. All patients received a 40 mg injection of Drotaverine hydrochloride intramuscularly at 3 to 5 cm dilation by a single nurse. Then, patients were monitored until delivery, and the duration of labor from the time of injection until delivery was noted. Statistical analysis: All the collected information was analyzed through SPSS version 25. Age, gestational age, cervical dilat-ation, and duration of labour was calculated and presented as mean and standard deviation.

labor with cervical dilation of 3 to 5 cm with 2 to 3

#### **RESULTS:**

The current study included 150 patients, with baseline features exhibited in table 1. The mean age of the patients was 23.67 + 3.23 years. The mean gestational age at the time of presentation was 38.26 + 1.26 weeks. The mean cervical dilation at the time of presentation was  $4.32 \pm 1.15$  cm. The minimum dilation was 3.22 cm and the maximum dilation was 4.96 cm.

Features	Mean ± SD
Age of patients (years)	23.67 + 3.23
Gestational age (weeks)	38.26 + 1.26
Cervical dilatation (cm)	4.32 ± 1.15

#### Table 1: n = number of patients; SD = standard deviation; cm = centimeter

The mean duration of labor after receiving Drotaverine hydrochloride injection is shown in table 2. The mean duration of 1st, 2nd, and 3rd stages of labor was  $4.34 \pm 0.094$  hours,  $22.07 \pm 4.25$  minutes, and  $10.42 \pm 3.35$  minutes, respectively. The mean total duration of labor was 4.94 + 0.33 hours.

#### Table 2: Duration of labor after receiving Drotaverine hydrochloride injection

Variables	Mean ± SD
Duration of 1st stage of labor (hours)	4.34 + 0.094
Duration of 2nd stage of labor (minutes)	22.07 + 4.25
Duration of 3rd stage of labor (minutes)	10.42 + 3.35
Total duration of labor (hours)	4.94 + 0.33

# Table 2: SD = standard deviation DISCUSSION:

Prolonged labor is multifactorial and is associated with adverse fetomaternal outcomes. It is more common in primigravid women, increasing the likelihood of cesarean delivery and other complications. However, normal vaginal delivery has always been preferred for its socioeconomic benefits. Therefore, various pharmacological and physiological methods are available to lessen the duration of labor and facilitate normal vaginal delivery. These include amniotomy, the use of oxytocin and different spasmolytic drugs. Drotaverine hydrochloride is a relatively new spasmolytic drug used to reduce muscle spasms. However, its efficacy in lessening the duration of 1st stage of labor is not well established in local settings, which necessitated conducting the current study. This study was intended to analyze the mean duration of labor after Drotaverine hydrochloride injection in primigravid women pre-senting in the active phase of labor. The cur-rent study documented that the mean duration of the 1st stage of labor was 4.34 ± 0.094 hours, and the mean total duration of labor was 4.94 ± 0.33 hours. Multiple studies have reported the impact of Drotaverine hydrochloride injection on the dur-ation of labor <sup>12</sup>, <sup>13</sup>, <sup>15</sup>, <sup>16</sup>. Loke et al. reported that admin-istration of Drotaverine hydrochloride, in the act-I've phase of labor, effectively reduced the length of labor by promoting the cervical dilatation <sup>17</sup>. Similarly, a study performed in Lahore, Pakistan, also revealed that Drotaverine hydrochloride short-ened the duration of the first stage of labor. The duration of the 1st stage of labor was 206.80 ± 24.45 minutes following the administration of Drotaverine hydrochloride injection<sup>16</sup>. Another study validated the findings of this study, showing that the first stage of labor was shortened by 15% and the second stage by 19% after administering Drotaverine hydrochloride <sup>15</sup>. One more study reported that the mean length of the active phase of labor was 4.21 ± 1.98 hours after Drotaverine hydrochloride injection<sup>2</sup>, comparable to the findings of the current study. Aslam also documented that the length of the active phase of labor was 2.08±0.82 hours, compared to 3.10±0.86 hours in the control group <sup>18</sup>. An Indian study also supp-orted the outcomes of the current study. It repo-rted that the length of 1st stage of labor, in pati-ents receiving Drotaverine hydrochloride, was 3.34 ± 1.09 hours <sup>19</sup>. Shahid et al. revealed that the average length of active phase of labor was 203-.77±8.21 minutes in patients receiving Drotaverine hydrochloride<sup>20</sup>. These results are in agreement with those of the current study. Nevertheless, the present study also had some limitations. Firstly, the small sample size narrowed down the gene-ralizability of the results. Secondly, no control gro-up was included in the study, limiting the causal link between the treatment and the outcome. A larger casecontrol study should be performed to ascertain the findings of the current study.

#### **CONCLUSION:**

In conclusion, Drotaverine hydrochloride effectively reduced the mean length of labor in the primigravidas presented in the active phase of labor. Therefore, it can be administered to alleviate spasms and accelerate cervical dilatation, thereby facilitating safe and prompt delivery, and reducing the incidence of feto-maternal complications.

#### **Author's contribution**

**ZAK:** Idea conception, Data collection, main write up **SKK:** Data collection, write up **MU:** Literature collection, discussion

#### **REFERENCES:**

- **01.** Carlhäll S, Nelson M, Svenvik M, Axelsson D, Blomberg M. Maternal childbirth experience and time in labor: a population-based cohort study. Sci Rep. 2022;12(1):11930.
- **02.** Ikeotuonye AC, Umeora OJ, Nwafor JI, Ojumah BO, Ekwunife IC, Dimejesi IB. Drotaverine to shorten the duration of labour in primi-gravidas: a randomised, double-blind, placebocontrolled trial. Afr Health Sci. 2022;22-(3):108-16.
- O3. Young C, Bhattacharya S, Woolner A, Ingram A, Smith N, Raja E-A, et al. Maternal and perinatal outcomes of prolonged second stage of lab-our: a historical cohort study of over 51,000 women. BMC Preg Childbirth. 2023;23(1):467.
- 04. McKinney JR, Allshouse AA, Heyborne KD. Duration of labor and maternal and neonatal morbidity. Am J of Obstet Gynecol MFM. 2019;1(3):100032.
- **05.** Pitchaimuthu N, Bhaskaran S. Labor pattern among primigravida in local population.J Ob-stet Gynecol Ind. 2018;68(6):482-6.
- 06. Bakker W, Sandberg EM, Keetels S, Schoones JW, Kujabi ML, Maaløe N, et al. Inconsistent definitions of prolonged labor in international literature: a scoping review. AJOG Glob Rep. 2024:100360.
- Rohwer AC, Khondowe O, Young T. Antispasmodics for labour. Cochrane DB Syst Rev. 2013(6):CD009243.
- 08. Tehalia Manpreet K, Sajjan Gouramba R,

Korbu Jyothi VS, Biradar R. A comparative study of Hyoscine butylbromide versus Drotaverine hydrochloride in first stage of labor. J Obstet Gynecol Ind. 2008;58(3)-:230-34.

- O9. Alhafez L, Berghella V. Evidence-based labor management: first stage of labor (part 3). Am J Obstet Gynecol MFM. 2020;2(4):-100185.
- Jumbo AI, Nonye-Enyidah EI, Iwo-Amah RS, Enyidah N, Ngeri B, Ohaka C, et al. Prevention of prolonged labour in term nulliparas with oxytocin alone versus with oxy-tocin and an antispasmodic. Magna Sci Adv Res Rev. 2023;8(01):152-60.
- Gupta B, Nellore V, Mittal S. Drotaverine hydrochloride versus hyoscine-N-butylbromide in augmentation of labor. Int J Gynecol Obstet. 2008;100(3):244-7.
- Ibrahim MI, Alzeeniny HA, Ellaithy MI, Salama AH, Abdellatif MA. Drotaverine to improve progression of labor among nulliparous women. Int J Gynecol Obstet. 2014;124(2):-112-7.
- Sulochana M, Goud NS, Balajojamma O. A COMPARATIVE STUDY OF VALETHAMATE BROMIDE AND DROTAVERINE HYDRO-CHLORIDEON CERVICAL DILATATION IN ACTIVE LABOUR AT A TERTIARY CARE HO-SPITAL. Eur J Molecul Clin Med. 2022;9-(3):805-14.
- Samskruthi K, Hebbar S, Pandey D, Upadhyaya R, Lobo V. Drotaverine to improve progression of labour among parturient women-a case control study. Int J Reprod Contracept Obstet Gynecol. 2023;12(9):-2772-7.
- Singh K, Jain P, Goel N, Saxena A. Drotaverine hydrochloride for augmentation of labor. Int J Gynecol Obstet. 2004;84(1):17-22.

- SABEEN N, LATIF F, FAZIL A. Drotaverine for Acceleration of Labour with Reduced Incidence of Caerserean Section and No Postpartum Haemorrhage. J Fatima Jinnah Med Univ. 2016;10(4):32-6.
- Loke C, Pavan Soleti DDBP, Chinnapaka P, Muralidhar C. Comparison of the Effectiveness of Drotaverine Hydrochloride and Valethamate Bromide in Promoting Cervical Dilatation during Active Labour: An Observational study. J Cardiovasc Dis Res. 2023;14-(05):609-14.
- Aslam R. Drotaverine for acceleration of labour in terms of cervical dilatation. EPH -

Int J Med Health Sci. 2023;9(3):18-38.

- Kausar U, Siddiqui N. To compare the efficacy of Drotaverine Hydrochloride with Hyoscine Butyl bromide for increasing the rate of cerv-ical dilatation. Int J Reprod Contracept Obstet Gynecol. 2017;6(4):1615.
- 20. Shahid M, Arif N, Hamid I, Arif S, Naeem A. Effic-acy of Phloroglucinol vs Drotaverine Hydroc-hloride in Shortening in Primigravidae at Term the Active Phase of the First Stage of Labor: Phloroglucinol vs Drotaverine Hydroc-hloride in Shortening the First Stage of Labor. Pak Biomed J 2022;5(6):-246-9.